ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,615.35
      0.55%
      US Tech 100
      19,804.00
      0.64%
      Dow Jones
      40,000.90
      0.62%
      Brent Oil
      84.57
      0.00%
      Bitcoin
      58,595.85
      1.22%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NYSE
      6. AbbVie Inc (ABBV)

      7. AbbVie Inc (ABBV) News

      ABBV

      AbbVie (ABBV)

      AbbVie Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NYSE:ABBV
      DateTimeSourceHeadlineSymbolCompany
      05/27/20225:45AMPR Newswire (US)ABBV SHAREHOLDER ALERT: Jakubowitz Law Reminds AbbVie Shareholders of a Lead Plaintiff Deadline of June 6, 2022NYSE:ABBVAbbVie Inc
      05/27/20223:15AMPR Newswire (US)The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Ulcerative ColitisNYSE:ABBVAbbVie Inc
      05/27/20223:00AMPR Newswire (US)The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Risankizumab (SKYRIZI®) in Crohn's DiseaseNYSE:ABBVAbbVie Inc
      05/26/20225:06AMTipRanksAbbVie (ABBV) Received its Third Buy in a RowNYSE:ABBVAbbVie Inc
      05/25/20224:59PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:ABBVAbbVie Inc
      05/25/202210:38AMDow Jones NewsTeva Pharmaceutical Settles Opioid Suit With West VirginiaNYSE:ABBVAbbVie Inc
      05/25/20228:00AMPR Newswire (US)AbbVie to Present at the Bernstein 38th Annual Strategic Decisions ConferenceNYSE:ABBVAbbVie Inc
      05/25/20225:45AMPR Newswire (US)SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of AbbVie Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 6, 2022 - (NYSE: ABBV)NYSE:ABBVAbbVie Inc
      05/24/20228:00AMPR Newswire (US)AbbVie Showcases its Leadership in Rheumatology Research with New Data Across Multiple Inflammatory Joint Diseases at the EULAR 2022 CongressNYSE:ABBVAbbVie Inc
      05/23/202210:06PMTipRanksAbbVie (ABBV) Receives a New Rating from SVB SecuritiesNYSE:ABBVAbbVie Inc
      05/23/20228:00AMPR Newswire (US)AbbVie Presents Positive Data from Phase 3 Study of Cariprazine (VRAYLAR®) for the Adjunctive Treatment of Major Depressive Disorder at 2022 APA Annual MeetingNYSE:ABBVAbbVie Inc
      05/23/20222:00AMPR Newswire (US)CHMP Recommends European Commission Approval of Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderate to Severe Ulcerative ColitisNYSE:ABBVAbbVie Inc
      05/20/20225:04PMEdgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NYSE:ABBVAbbVie Inc
      05/20/20229:02AMDow Jones NewsAbbVie Seeks FDA OK for ABBV-951 in Advanced Parkinson's DiseaseNYSE:ABBVAbbVie Inc
      05/20/20228:15AMPR Newswire (US)AbbVie Submits New Drug Application to U.S. FDA for Investigational ABBV-951 (Foscarbidopa/Foslevodopa) for the Treatment of Advanced Parkinson's DiseaseNYSE:ABBVAbbVie Inc
      05/20/20225:45AMPR Newswire (US)ABBV SHAREHOLDER ALERT: Jakubowitz Law Reminds AbbVie Shareholders of a Lead Plaintiff Deadline of June 6, 2022NYSE:ABBVAbbVie Inc
      05/18/20225:13PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:ABBVAbbVie Inc
      05/18/20225:13PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:ABBVAbbVie Inc
      05/18/20225:45AMPR Newswire (US)SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of AbbVie Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 6, 2022 - (NYSE: ABBV)NYSE:ABBVAbbVie Inc
      05/16/20226:23PMDow Jones NewsBerkshire Hathaway Exited Bristol Myers and AbbVie Stakes in 1QNYSE:ABBVAbbVie Inc
      05/16/20228:00AMPR Newswire (US)AbbVie to Showcase Depth of Gastroenterology Portfolio and Pipeline at Digestive Disease Week®NYSE:ABBVAbbVie Inc
      05/16/20227:30AMPR Newswire (US)AbbVie and Cugene Announce Collaboration in Autoimmune DiseasesNYSE:ABBVAbbVie Inc
      05/13/20225:47PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:ABBVAbbVie Inc
      05/13/20225:45AMPR Newswire (US)ABBV SHAREHOLDER ALERT: Jakubowitz Law Reminds AbbVie Shareholders of a Lead Plaintiff Deadline of June 6, 2022NYSE:ABBVAbbVie Inc
      05/12/202211:39AMPR Newswire (US)AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual CongressesNYSE:ABBVAbbVie Inc
      05/12/202211:03AMTipRanksPharma Stocks: The Perfect Cure in an Unhealthy Environment?NYSE:ABBVAbbVie Inc
      05/12/20228:49AMTipRanksAbbVie (ABBV) Received its Third Buy in a RowNYSE:ABBVAbbVie Inc
      05/12/20228:30AMPR Newswire (US)AbbVie Awards 45 Scholarships to U.S. Students Living with Chronic, Immune-Mediated Diseases in Their Pursuit of Higher EducationNYSE:ABBVAbbVie Inc
      05/11/202211:07AMDow Jones NewsCorrection to AbbVie Upadacitinib StoryNYSE:ABBVAbbVie Inc
      05/11/20229:38AMDow Jones NewsAbbVie: Upadacitinib Achieved Clinical Remission at One Year in Crohn's DiseaseNYSE:ABBVAbbVie Inc
       Showing the most relevant articles for your search:NYSE:ABBV